催乳素通过CD36通路改善肝脂肪变性
研究评估了催乳素(PRL)与非酒精性脂肪性肝病(NAFLD)的关联,发现超声诊断NAFLD者循环PRL水平低于无NAFLD者,活检证实的重度肝脂肪变性者PRL低于轻中度者。细胞实验显示PRL/PRLR通过下调CD36减少脂质积聚。
要点
- 超声诊断NAFLD者循环PRL水平低于无NAFLD者。
- 活检证实的重度肝脂肪变性者PRL水平低于轻中度者。
- 细胞实验中PRL/PRLR通过CD36通路改善肝脂质积聚。
核心结论
- PRL/PRLR通过CD36通路改善肝脂质积聚,提示PRL/PRLR与NAFLD存在负相关。
研究设计与样本
- 评估456例超声诊断NAFLD患者、403例超声诊断无NAFLD对照及85例代谢手术中获得肝组织学个体的血清PRL水平。
- 在FFA处理的HepG2细胞中检测PRLR或CD36过表达及PRLR敲低对肝脂质代谢的影响。
主要发现
- 超声诊断NAFLD男性PRL为7.9(范围5.9-10.3)µg/L,低于无NAFLD男性9.1(范围6.8-13.0)µg/L,p=0.002。
- 超声诊断NAFLD女性PRL为8.7(范围6.1-12.4)µg/L,低于无NAFLD女性11.6(范围8.2-16.1)µg/L,p<0.001。
- 活检证实的重度肝脂肪变性男性PRL为8.3(范围5.4-9.5)µg/L,低于轻中度男性9.7(范围7.1-12.3)µg/L,p=0.031。
- 活检证实的重度肝脂肪变性女性PRL为8.5(范围4.2-10.6)µg/L,低于轻中度女性9.8(范围8.2-15.7)µg/L,p=0.027。
- NAFLD患者肝PRLR基因表达显著降低且与CD36基因表达负相关;FFA处理的HepG2细胞中PRL处理或PRLR过表达显著降低CD36表达和脂质含量,沉默PRLR后该效应被消除,过表达CD36显著减弱PRL介导的脂质含量改善。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Prolactin (PRL) is a multifunctional polypeptide with effects on metabolism, however, little is known about its effect on hepatic steatosis and lipid metabolism. Herein, we aimed to assess the role of PRL in the development of non-alcoholic fatty liver disease (NAFLD). METHODS: The serum PRL levels of 456 patients with NAFLD, 403 controls without NAFLD diagnosed by ultrasound, and 85 individuals with liver histology obtained during metabolic surgery (44 female and 30 male patients with NAFLD and 11 age-matched non-NAFLD female individuals) were evaluated. The expression of the gene encoding the prolactin receptor (PRLR) and signalling molecules involved in hepatic lipid metabolism were evaluated in human liver and HepG2 cells. The effects of overexpression of PRLR or fatty acid translocase (FAT)/CD36 or knockdown of PRLR on hepatic lipid metabolism were tested in free fatty acid (FFA)-treated HepG2 cells. RESULTS: Circulating PRL levels were lower in individuals with ultrasound-diagnosed NAFLD (men: 7.9 [range, 5.9-10.3] µg/L; women: 8.7 [range, 6.1-12.4] µg/L) than those with non-NAFLD (men: 9.1 [range, 6.8-13.0] µg/L, p = 0.002; women: 11.6 [range, 8.2-16.1] µg/L, p <0.001). PRL levels in patients with biopsy-proven severe hepatic steatosis were lower compared with those with mild-to-moderate hepatic steatosis in both men (8.3 [range, 5.4-9.5] µg/L vs. 9.7 [range, 7.1-12.3] µg/L, p = 0.031) and women (8.5 [range, 4.2-10.6] µg/L vs. 9.8 [range, 8.2-15.7] µg/L, p = 0.027). Furthermore, hepatic PRLR gene expression was significantly reduced in patients with NAFLD and negatively correlated with CD36 gene expression. In FFA-induced HepG2 cells, PRL treatment or PRLR overexpression significantly reduced the expression of CD36 and lipid content, effects that were abrogated after silencing of PRLR. Furthermore, overexpression of CD36 significantly reduced the PRL-mediated improvement in lipid content. CONCLUSIONS: Our results reveal a novel association between the central nervous system and the liver, whereby PRL/PRLR improved hepatic lipid accumulation via the CD36 pathway. LAY SUMMARY: Our clinical study suggests a negative association between prolactin (PRL)/prolactin receptor (PRLR) and the presence of non-alcoholic fatty liver disease (NAFLD). Using cell experiments, we found that PRL ameliorates hepatic steatosis via the hepatic PRLR and fatty acid translocase (FAT)/CD36, a key transporter of free fatty acid uptake in liver. Our findings suggest a novel approach to improving NAFLD using PRL and PRLR. Clinical trial number: NCT03296605.
引用
- Zhang P, Ge Z, Wang H, et al. Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol. 2018. PMID: 29452209. doi:10.1016/j.jhep.2018.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。